10
Participants
Start Date
July 13, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
August 31, 2026
Ruxolitinib
Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
Dexamethasone
Given intravenously (IV) or orally (PO) twice a day for 8 weeks
Etoposide
Given intravenously (IV) once a week for 8 weeks
Cohen Children's Medical Center, New Hyde Park
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
John Hopkins University, Baltimore
Levine Children's Hospital, Charlotte
St. Jude Children's Research Hospital, Memphis
Children's Wisconsin/Medical College of Wisconsin, Milwaukee
University of Texas Southwestern Medical Center, Dallas
Texas Children's Hospital, Houston
Phoenix Children's Hospital, Phoenix
Children's Hospital of Orange County, Orange
University of California San Francisco, San Francisco
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Incyte Corporation
INDUSTRY
North American Consortium for Histiocytosis
OTHER
Cures Within Reach
OTHER
St. Jude Children's Research Hospital
OTHER